Thursday, April 20, 2023
9:07 AM EST – Marvel Biosciences Corp : Announces that along with its wholly owned subsidiary, Marvel Biotechnology Inc., it has completed the dosing portion of the 4-week good laboratory practice FDA investigational new drug enabling dose-ranging dog and rat studies for its lead drug candidate MB-204. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson’s disease, and Alzheimer’s disease and improved concentration. Marvel Biosciences Corp (V.MRVL) shares were unchanged at 0.1.
Stocks in Play: Marvel Biosciences Corp, Thu, 20 Apr 2023 09:27:06 EST